

## **Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024**

ROCKVILLE, Md., Jan. 23, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference, taking place virtually on February 1, 2024.



At the conference, Dr. Dritschilo will discuss details of the Company's recent FDA approval to proceed with the Phase II clinical trial of Ropidoxuridine for treatment of patients with glioblastoma, as well as other key areas of progress as Shuttle aims to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment.

### **Company Webcast**

The webcasted fireside chat will take place at 1:15pm ET on Thursday, February 1, 2024. The webcast can be accessed at <https://wsw.com/webcast/lytham10/shph/2099184> or on the Company's website at <https://shuttlepharma.com/investor-relations/>. The webcast will also be available for replay following the event.

### **1x1 Meetings**

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [1x1@lythampartners.com](mailto:1x1@lythampartners.com) or register for the event at

<https://lythampartners.com/select2024invreg/>.

Further information on the conference is available at <https://lythampartners.com/select2024>.

### **About Shuttle Pharmaceuticals**

Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at [www.shuttlepharma.com](http://www.shuttlepharma.com).

### **Shuttle Pharmaceuticals**

Anatoly Dritschilo, M.D., CEO

240-403-4212

[info@shuttlepharma.com](mailto:info@shuttlepharma.com)

### **Investor Contacts**

Lytham Partners, LLC

Robert Blum

602-889-9700

[shph@lythampartners.com](mailto:shph@lythampartners.com)

 View original content to download

multimedia:<https://www.prnewswire.com/news-releases/shuttle-pharma-to-participate-in-a-first-side-chat-at-the-lytham-partners-2024-investor-select-conference-on-february-1-2024-302042226.html>

SOURCE Shuttle Pharmaceuticals Holdings, Inc.